Surgical Science Sweden AB (publ) (SUSRF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Surgical Science Sweden AB (publ) (SUSRF) trades at $4.00 with AI Score 55/100 (Grade B). Surgical Science Sweden AB (publ) specializes in virtual reality surgical simulation. Market cap: $204M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for SUSRF: SUSRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SUSRF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SUSRF: 1/2 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Surgical Science Sweden AB (publ) (SUSRF) Healthcare & Pipeline Overview
Surgical Science Sweden AB (publ) develops and markets virtual reality surgical simulators, offering evidence-based training solutions for laparoscopic, endoscopic, and robotic procedures. With a focus on enhancing surgical skills and patient safety, the company addresses the growing demand for advanced medical training technologies within the healthcare sector.
What Is the Investment Thesis for SUSRF?
Surgical Science Sweden AB (publ) presents a notable research candidate within the growing market for surgical simulation. The company's focus on virtual reality training solutions for laparoscopic, endoscopic, and robotic surgery aligns with the increasing demand for advanced medical education and patient safety. With a P/E ratio of 24.06 and a profit margin of 6.7%, the company demonstrates financial stability and growth potential. Key value drivers include the expansion of its product portfolio, penetration into new geographic markets, and the increasing adoption of simulation-based training in healthcare. Ongoing catalysts include partnerships with medical institutions and the development of new simulation modules for emerging surgical techniques. Potential risks include competition from other simulation providers and the adoption rate of VR technology in surgical training.
Based on FMP financials and quantitative analysis
SUSRF Key Highlights
- Market Cap of $204M indicates a relatively small but established player in the medical simulation market.
- P/E Ratio of 24.06 suggests the company is valued reasonably compared to its earnings.
- Profit Margin of 6.7% demonstrates profitability, although there is room for improvement compared to industry leaders.
- Gross Margin of 63.9% highlights the company's ability to efficiently manage production costs.
- Beta of 0.59 indicates lower volatility compared to the overall market, suggesting a more stable investment.
Who Are SUSRF's Competitors?
SUSRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AVCTF Avacta Group Plc | $0.91 | +0.00% | $425M | 47 |
| BOVNF BioInvent International AB (publ) | $3.29 | +0.00% | $216M | 51 |
| CLHLF COLTENE Holding AG | $61.16 | +0.00% | $365M | 49 |
| COGZF Cogstate Limited | $1.99 | +0.00% | $338M | 45 |
| HUMDF Hua Medicine (Shanghai) Ltd. | $0.34 | +0.00% | $339M | 49 |
| SPOK Spok Holdings, Inc. | $10.46 | -1.74% | $219M | 83 |
| VPAHF Volpara Health Technologies Limited | $0.74 | +36.63% | $188M | 60 |
| SMFR Sema4 Holdings Corp. | $0.31 | +26.78% | $246M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SUSRF's Key Strengths?
- Innovative virtual reality technology.
- Comprehensive product portfolio.
- Strong relationships with medical institutions.
- Established brand reputation.
What Are SUSRF's Weaknesses?
- Relatively small market capitalization.
- Limited geographic presence.
- Dependence on technological advancements.
- Profit margin could be higher.
What Could Drive SUSRF Stock Higher?
- Increasing adoption of virtual reality simulation in surgical training programs.
- Strategic partnerships with leading medical institutions to expand market reach.
- Development and launch of new simulation modules for emerging surgical techniques.
- Expansion into new geographic markets with high demand for surgical training.
- Integration of artificial intelligence to enhance the realism and effectiveness of surgical simulations.
What Are the Key Risks for SUSRF?
- Competition from established medical device companies with larger resources.
- Technological obsolescence due to rapid advancements in virtual reality technology.
- Regulatory changes in the healthcare industry affecting the adoption of simulation-based training.
- Economic downturns leading to budget cuts in hospitals and training centers.
- Limited liquidity due to trading on the OTC market.
What Are the Growth Opportunities for SUSRF?
- Expansion into Emerging Markets: Surgical Science has the opportunity to expand its presence in emerging markets, where the demand for advanced medical training is growing rapidly. These markets often lack access to experienced surgeons and advanced medical facilities, making simulation-based training a valuable solution. By establishing partnerships with local hospitals and educational institutions, Surgical Science can tap into this underserved market and drive revenue growth. Timeline: 2-3 years. Market Size: Significant growth potential in Asia-Pacific and Latin America.
- Development of New Simulation Modules: Surgical Science can drive growth by continuously developing new simulation modules that address emerging surgical techniques and procedures. This includes expanding its offerings for robotic surgery, minimally invasive surgery, and other specialized areas. By staying at the forefront of surgical innovation, the company can attract new customers and retain existing ones. Timeline: Ongoing. Market Size: Continuous expansion based on new surgical advancements.
- Strategic Partnerships with Medical Institutions: Collaborating with leading medical institutions and universities can provide Surgical Science with access to valuable research, clinical expertise, and distribution channels. These partnerships can help the company refine its products, validate its training methodologies, and increase its market reach. Timeline: Ongoing. Market Size: Increased market penetration and brand recognition.
- Integration of Artificial Intelligence: Integrating AI into its simulation platforms can enhance the realism and effectiveness of surgical training. AI can be used to provide personalized feedback, adapt the difficulty level to the trainee's skill level, and simulate complex surgical scenarios. This can improve the learning experience and lead to better patient outcomes. Timeline: 3-5 years. Market Size: Enhanced training effectiveness and competitive advantage.
- Subscription-Based Revenue Model: Transitioning to a subscription-based revenue model can provide Surgical Science with a more predictable and recurring revenue stream. This model involves offering customers access to its simulation platforms and content on a subscription basis, rather than through one-time purchases. This can improve customer retention and increase the lifetime value of each customer. Timeline: 1-2 years. Market Size: Stable and recurring revenue stream.
What Opportunities Does SUSRF Have?
- Expansion into emerging markets.
- Development of new simulation modules.
- Strategic partnerships with medical institutions.
- Integration of artificial intelligence.
What Threats Does SUSRF Face?
- Competition from established medical device companies.
- Technological obsolescence.
- Regulatory changes in the healthcare industry.
- Economic downturns affecting hospital budgets.
What Are SUSRF's Competitive Advantages?
- Proprietary virtual reality technology.
- Strong relationships with leading medical institutions.
- Comprehensive suite of simulation products.
- Established brand reputation in the surgical simulation market.
What Does SUSRF Do?
Surgical Science Sweden AB (publ), founded in 1999 and headquartered in Gothenburg, Sweden, is a pioneering company in the field of virtual reality surgical simulation. The company develops and markets VR simulators designed to provide evidence-based training for laparoscopic and endoscopic surgical procedures. Its flagship product, the LapSim training system, includes LapSim ST, tailored for surgical technologists and assistants, and LapSim essence, a portable VR simulator. Surgical Science also offers the EndoSim system for endoscopy training, TeamSim for inter-professional teamwork development in surgery, Simball Box for velocity feedback, Simbionix simulators, and robotic surgery simulators. These products aim to enhance surgical skills, improve patient outcomes, and reduce the learning curve for surgeons and medical staff. Surgical Science's simulators are used in hospitals, training centers, and educational institutions worldwide, positioning the company as a key player in the advancement of surgical education and patient safety.
What Products and Services Does SUSRF Offer?
- Develops virtual reality simulators for surgical training.
- Offers simulators for laparoscopic procedures.
- Provides simulators for endoscopic procedures.
- Creates simulators for robotic surgery training.
- Offers training systems for surgical technologists and assistants.
- Develops platforms for inter-professional teamwork education in surgery.
- Provides tools for velocity feedback during surgical training.
How Does SUSRF Make Money?
- Sells virtual reality surgical simulators to hospitals and training centers.
- Generates revenue through the sale of simulation modules and software updates.
- Offers service and maintenance contracts for its simulators.
- Partners with medical institutions for research and development.
What Industry Does SUSRF Operate In?
Surgical Science Sweden AB (publ) operates within the healthcare information services industry, specifically focusing on medical simulation. The market for surgical simulation is growing due to the increasing emphasis on patient safety, the need for standardized training, and the adoption of new surgical techniques. The competitive landscape includes companies offering similar simulation solutions, such as AVCTF (Avantis Medical Systems), BOVNF (Bovie Medical), CLHLF (ClearSign Technologies), COGZF (Cogentix Medical), and HUMDF (Humacyte). Surgical Science differentiates itself through its focus on VR technology and its comprehensive suite of simulation products.
Who Are SUSRF's Key Customers?
- Hospitals and medical centers.
- Surgical training centers.
- Universities and medical schools.
- Medical device companies.
ROE 1%Key Financial Metrics
Return on equity for Surgical Science Sweden AB (publ) stands at 1.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.1%, showing how much profit it generates from its asset base. SUSRF trades at a trailing price-to-earnings ratio of 29.52, above the Healthcare sector average of ~23x. Its free cash flow yield is 6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.44 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.4%, the inverse of the P/E and a quick read on earnings relative to price.
Surgical Science Sweden AB (publ) (SUSRF) Valuation Context
Valued at $204M, SUSRF is classified as a micro-cap stock. Relative to its peer group, SUSRF's quantitative score of 55/100 is roughly in line with the peer average of 48/100.
Company Profile
Surgical Science Sweden AB (publ) operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Gothenburg, SE. The company is led by CEO Tom Englund. SUSRF has traded publicly since 2021.
F-Score 6/9Financial Health
Surgical Science Sweden AB (publ)'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.75 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Surgical Science Sweden AB (publ) revenue of about $994.7M for fiscal 2026, with EPS near $1.96. The estimate reflects 3 contributing analysts.
SUSRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its growth potential.
- Community sentiment has been increasingly positive, with discussions highlighting the company's innovative surgical simulation products gaining traction.
- Recent partnerships and collaborations in the healthcare sector have bolstered the company's reputation, enhancing its market position.
- The growing demand for advanced surgical training solutions is driving interest, positioning Surgical Science as a leader in this niche.
Bear Case
- Concerns over market competition have surfaced, with new entrants challenging Surgical Science's established products.
- Some community members express skepticism about the company's ability to scale operations effectively, citing potential operational hurdles.
- Recent market developments indicate a cautious approach from investors, reflecting uncertainty about the company's long-term profitability.
- Regulatory changes in healthcare could pose challenges, creating potential barriers for Surgical Science's product adoption and expansion.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SUSRF Latest News
No recent news available for SUSRF.
SUSRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SUSRF.
Price Targets
Wall Street price target analysis for SUSRF.
SUSRF MoonshotScore
What does this score mean?
The MoonshotScore rates SUSRF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Tom Englund
CEO
Tom Englund serves as the CEO of Surgical Science Sweden AB (publ), leading a team of 274 employees. His background includes extensive experience in the medical technology sector, with a focus on strategic leadership and business development. He has a proven track record of driving growth and innovation in healthcare companies. Englund's expertise spans product development, market expansion, and building strong relationships with key stakeholders in the medical community.
Track Record: Under Tom Englund's leadership, Surgical Science has expanded its product portfolio and strengthened its position in the surgical simulation market. He has overseen the development of new simulation modules for emerging surgical techniques and has forged strategic partnerships with leading medical institutions. His focus on innovation and customer satisfaction has contributed to the company's growth and success.
SUSRF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Surgical Science Sweden AB (publ) may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier is generally associated with higher risk and less regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Less regulatory oversight compared to major exchanges.
- Potential for delisting or trading suspensions.
- Increased risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's liquidity and trading volume.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal proceedings against the company.
- The company has been in operation since 1999.
- The company has a market capitalization of $204M.
- The company has a positive profit margin of 6.7%.
- The company has a gross margin of 63.9%.
- The company employs 274 people.
What Investors Ask About Surgical Science Sweden AB (publ) (SUSRF) — Healthcare
What does the AI Score mean for SUSRF?
SUSRF holds an AI Score of 55/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Surgical Science Sweden AB (publ) specializes in virtual reality surgical simulation. Their products enhance training for laparoscopic, endoscopic, and robotic surgical procedures, improving …
What does Surgical Science Sweden AB (publ) do?
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based laparoscopic and endoscopic training. Their simulators are designed to enhance surgical skills, improve patient outcomes, and reduce the learning curve for surgeons and medical staff. The company's products include LapSim, EndoSim, TeamSim, and Simball Box, which are used in hospitals, training centers, and educational institutions worldwide.
What are the main risks for SUSRF?
The main risks for Surgical Science Sweden AB (publ) include competition from established medical device companies, technological obsolescence, regulatory changes in the healthcare industry, and economic downturns affecting hospital budgets. Additionally, the company faces risks associated with trading on the OTC market, such as limited liquidity and less regulatory oversight. Investors should carefully consider these risks before investing in SUSRF.
What are the key factors to evaluate for SUSRF?
Surgical Science Sweden AB (publ) (SUSRF) holds an AI score of 55/100 (moderate). Not financial advice.
How frequently does SUSRF data refresh on this page?
SUSRF's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SUSRF's recent stock price performance?
Surgical Science Sweden AB (publ) (SUSRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative virtual reality technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SUSRF overvalued or undervalued right now?
Surgical Science Sweden AB (publ) (SUSRF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SUSRF before investing?
Before investing in Surgical Science Sweden AB (publ) (SUSRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SUSRF to a portfolio?
Key strength of Surgical Science Sweden AB (publ) (SUSRF): Innovative virtual reality technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may not be fully comprehensive.
- AI analysis is pending and may provide further insights into the company's prospects.
- OTC market investments carry higher risks than investments in stocks listed on major exchanges.